ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trilaciclib

Also written as “Trilaciclib” and “Trilaciclib, carboplatin, etoposide,or Topotecan”.

Its studies are mostly in Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageTrilaciclib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 12, 202314 company-led studies, 3 open or runningNext primary completion: Jul 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharmacosmosits history only112 open or runningphase 4since Apr 12, 2023Jul 8, 2015Oct 31, 2027phase 3 · NCT07473128
Simcere Pharmaceutical Group31 open or runningphase 4since Sep 28, 2021May 8, 2021Jul 15, 2027phase 3 · NCT07881705

Also a collaborator on its studies: Roche-Genentech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Simcere Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named trilaciclibINNProposed as its International Nonproprietary Name in WHO's List 117
  2. May 8, 2021First study: phase 3 study in Small Cell Lung CarcinomaFirst studyNCT04902885 · 95 enrolled · China
  3. Sep 28, 2021Phase 4 study in Small Cell Lung CarcinomaNCT05071703 · 30 enrolled · China
  4. Oct 12, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07881705 · 106 enrolled · China

Ahead

  1. Jul 15, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07881705

TargetBeta

CDK4 →CDK6 →read by rule
“A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
culmerciclibSino Biopharmaceuticalphase 311
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23

Studies

All 3 Simcere Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07881705Small Cell Lung Carcinoma · China3Active, not recruitingJul 15, 2027106
NCT05071703Small Cell Lung Carcinoma · China4CompletedApr 10, 202230
NCT04902885Small Cell Lung Carcinoma · China3CompletedDec 29, 202195

How it is read

Names in the registry

  • “Trilaciclib”, 13 entries
  • “Trilaciclib, carboplatin, etoposide,or Topotecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.